Company Overview

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company operating at the intersection of oncology drug development and mental health services. The company’s activities span pharmaceutical research focused on novel cancer therapies and the ownership and operation of outpatient psychiatric clinics. Its revenue to date has primarily been derived from clinical service operations rather than drug commercialization, as its therapeutic candidates remain in development.

The company was founded in 2020 and went public in 2021 through an initial public offering. Pasithea’s strategy has evolved to combine near-term revenue generation from mental health clinics with longer-term value creation from proprietary oncology assets. This dual-track model differentiates the company from pure-play biotech peers, though it also introduces operational complexity.

Business Operations

Pasithea operates through two primary business segments: Oncology Drug Development and Mental Health Services. The oncology segment centers on the development of PAS-004, a macrocyclic peptide drug candidate targeting mutant p53 proteins in solid tumors. This program is in preclinical or early clinical development, and no drug-related revenue is currently generated.

The mental health services segment operates outpatient psychiatric clinics under the Pasithea Clinics brand, providing services such as medication management and interventional psychiatry treatments. These clinics represent the company’s principal source of operating revenue. Operations are primarily domestic, with services delivered within the United States, and are supported by licensed clinicians and clinic management infrastructure.

Strategic Position & Investments

Strategically, Pasithea seeks to balance risk by funding drug development activities through clinic-generated revenue and external capital. Growth initiatives include advancing PAS-004 through clinical milestones and selectively expanding clinic operations where patient demand and reimbursement dynamics are favorable. The company has emphasized capital discipline and a focused pipeline rather than broad therapeutic diversification.

Pasithea has made targeted investments in intellectual property related to oncology therapeutics and continues to evaluate partnerships to accelerate development. No transformative acquisitions have been completed to date, and publicly disclosed subsidiaries are primarily aligned with clinic operations and intellectual property holding structures. Data inconclusive based on available public sources regarding large-scale strategic partnerships.

Geographic Footprint

Pasithea Therapeutics Corp. is headquartered in the United States, with corporate offices and executive management based domestically. Its mental health clinic operations are located within select U.S. states, giving the company a regional rather than national physical footprint.

The oncology development activities have an international dimension through research collaborations and contracted development activities, including relationships with research organizations outside the U.S. However, the company does not maintain significant owned facilities abroad, and its operational influence remains concentrated in North America.

Leadership & Governance

The company is led by an executive team with experience spanning biotechnology, clinical development, and healthcare operations. Leadership has articulated a strategy focused on disciplined capital allocation, clinical rigor, and leveraging operating businesses to support long-term therapeutic innovation.

Key executives include:

• Tiago Reis Marques – Chief Executive Officer
• Adam Shapiro – Chief Financial Officer
• Dr. Rony Abovitz – Chairman of the Board
• Dr. Marian Cruz – Chief Medical Officer

The board and management emphasize governance practices aligned with U.S. public company standards, with oversight of both clinical service compliance and drug development risk.